Drug Profile

Eneboparatide - Amolyt Pharma

Alternative Names: AZP-3601

Latest Information Update: 21 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Harvard Medical School; Massachusetts General Hospital
Developer Amolyt Pharma
Class Hormonal replacements; Peptide hormones; Peptides
Mechanism of Action Parathyroid hormone receptor type 1 agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Hypoparathyroidism
New Molecular Entity No

Highest Development Phases

Phase III Hypoparathyroidism

Most Recent Events

17 Mar 2025 Adverse events and efficacy data from a phase III CALYPSO trial in Hypoparathyroidism released by AstraZeneca
15 Jul 2024 Amolyt Pharma has been acquired by AstraZeneca
01 Jun 2024 Pharmacokinetics data from a preclinical studies in Hypoparathyroidism presented at the 106th Annual Meeting of the Endocrine Society (ENDO-2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com